Intrum AB (publ) (0H9P)
London Exchange · UK · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 1.780 |
|---|---|
| 52-week range | 1.780 – 10.565 |
| Return, 1 month / 3 months | −49.8% / −39.5% |
| Return, 1 year / 3 years | −81.6% / −83.9% |
| Trend | Below its 200-day average |
| RSI (14) | 20 |
| Volatility (1 year) | 97.9% |
| Worst drawdown (1 year) | -83.0% |
| Average daily value traded | 2.17M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Intrum is a credit management company based in Sweden. It purchases portfolios of overdue debts from banks and other lenders, then works to recover the money owed, and it also provides debt collection and loan servicing on behalf of clients. Its customers are mainly financial institutions and other businesses with unpaid receivables, and it operates across many European markets. The company handles both consumer and corporate debts through its collection and servicing operations.
On this site Intrum AB (publ) appears as a stock on the London Exchange (UK), code 0H9P, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Intrum AB (publ) (0H9P) trades on the London Exchange in UK. It last closed at SEK 1.780 on 23 October 2026.
Its price-based Market X-Ray is 13 out of 100 (a weak price profile), ranking 3,647 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 81.6% and over the last three months it fell 39.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 2 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -67.4% | ||
| From 52-week high | -83.0% | ||
| Momentum | 2 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -39.5% | ||
| 6-month return | -78.3% | ||
| 12-month return, skipping the last month | -63.3% | ||
| Stability (higher is calmer) | 5 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 97.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -83.0% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.17M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −36.4% |
|---|---|
| 1 month | −49.8% |
| 3 months | −39.5% |
| 6 months | −78.3% |
| 1 year | −81.6% |
| 3 years | −83.9% |
| 5 years | −95.4% |
Signals
| 50-day / 200-day average | 3.379 / 5.453 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.632 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Oct 2023 | SEK 6.7500 |
| 28 Apr 2023 | SEK 6.7500 |
| 3 May 2022 | SEK 13.5000 |
| 30 Apr 2021 | SEK 12.0000 |
| 7 May 2020 | SEK 11.0000 |
| 29 Apr 2019 | SEK 9.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.